In line, inhibition of CTSD in a model of murine NASH (LDLR−/− mice on a high-fat, high-cholesterol (HFC) diet) resulted in decreased levels of plasma cholesterol and triglycerides, in addition to a decrease in hepatic cholesterol and total triglycerides compared to NASH mice in which CTSD was not inhibited. Here, CTSD is linked to metabolic dysfunction-associated steatohepatitis.